
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
As bioconjugates grow more complex, experts discuss how orthogonal analytical methods fill characterization gaps.







